Pharmaceuticals

Psoriasis Biosimilars Market Insights On Growth Drivers, Trends, And Opportunities

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Psoriasis Biosimilars Market In 2026, And How Will Its Value Evolve By 2030?

The psoriasis biosimilars market has seen substantial growth in recent years. It is forecast to expand from $8.16 billion in 2025 to $9.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.3%. This historical growth can be attributed to factors such as the high cost of reference biologics, limited patient access to treatment, the increasing prevalence of moderate to severe psoriasis, enhanced physician awareness and prescriptions, and the initial approvals of TNF-alpha inhibitors.

The psoriasis biosimilars market is set for significant expansion in the coming years, with projections indicating it will reach $13.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.0%. This anticipated growth is driven by factors such as the introduction of new biosimilars for infliximab, etanercept, and adalimumab, the broadening of hospital and online pharmacy networks, increased spending on dermatology within healthcare, greater participation in patient assistance programs, and an uptick in clinical trials for novel biosimilars. Major developments expected during this forecast period include the increasing adoption of cost-effective psoriasis biosimilars, a heightened focus on patient access and affordability, the growing prevalence of subcutaneous and intravenous administration routes, the expansion of distribution channels through hospital and retail pharmacies, and the ongoing development of targeted therapies for various psoriasis types.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27399&type=smp

Which Important Drivers Are Guiding The Psoriasis Biosimilars Market Growth?

An increase in psoriatic arthritis diagnosis rates is anticipated to fuel the expansion of the psoriasis biosimilars market in the future. Psoriatic arthritis is defined as a persistent autoimmune disorder characterized by inflammation in both the joints and skin, frequently observed in those with a history of psoriasis. The diagnosis rates for psoriatic arthritis are on the rise, primarily attributed to enhanced screening procedures for individuals with psoriasis. These improvements facilitate earlier detection and more precise diagnoses by pinpointing subtle joint symptoms that might have previously been overlooked. Psoriasis biosimilars aid in the management of psoriatic arthritis by offering cost-effective alternatives to existing biologic therapies, thus effectively mitigating joint inflammation and skin manifestations. As an illustration, the National Psoriasis Foundation (NPF), a US-based non-profit patient advocacy organization, reported in August 2025 that approximately 1 in 3 individuals with psoriasis are affected by psoriatic arthritis. Furthermore, 2.4 million Americans live with psoriatic arthritis, and over 15% of individuals with psoriasis might also have undiagnosed psoriatic arthritis, underscoring both its growing recognition and continued underdiagnosis. Consequently, the escalating rates of psoriatic arthritis diagnoses are propelling the expansion of the psoriasis biosimilars market.

What Segment Categories Shape The Psoriasis Biosimilars Market Segment Landscape?

The psoriasis biosimilars market covered in this report is segmented –

1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars

2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis

3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars

2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars

3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars

4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars

5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars

What Trends Are Transforming The Psoriasis Biosimilars Market?

Leading companies within the psoriasis biosimilars market are concentrating on introducing novel solutions, such as biosimilars specifically for plaque psoriasis, to improve access to treatments, decrease healthcare expenses, and elevate patient outcomes. Biosimilars developed for plaque psoriasis serve as more affordable, highly analogous options to approved biologic drugs utilized for managing the persistent autoimmune skin condition characterized by red, flaky patches. For instance, in May 2025, Sandoz Group AG, a Switzerland-based firm focused on generic pharmaceuticals and biosimilars, launched the Pyzchiva autoinjector, which is the first commercially available ustekinumab biosimilar autoinjector. Pyzchiva has received approval for treating adults with plaque psoriasis, psoriatic arthritis, and Crohn’s disease, as well as pediatric patients aged six years and older (weighing over 60 kg) with plaque psoriasis. This autoinjector is engineered to boost patient adherence and enhance quality of life, featuring accurate automatic dosing, reduced pain during injection, a compact design, and flexible storage options to facilitate more comfortable self-administration.

Who Are The Companies Operating Across The Psoriasis Biosimilars Market Value Chain?

Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.

Get The Full Psoriasis Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report

Which Region Dominates The Psoriasis Biosimilars Market By Market Share?

North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Psoriasis Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report

Browse Through More Reports Similar to the Global Psoriasis Biosimilars Market 2026, By The Business Research Company

Connected Rail Market Report 2026

https://www.thebusinessresearchcompany.com/report/connected-rail-global-market-report

Rail Road Construction Market Report 2026

https://www.thebusinessresearchcompany.com/report/rail-road-construction-global-market-report

Freight Railcar Parts Market Report 2026

https://www.thebusinessresearchcompany.com/report/freight-railcar-parts-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795